Action ARch Biopartners (QB) - ACHFF

ARch Biopartners Inc (QB) (ACHFF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,5622

( -12,47% )

Prix Achat

0,5475

Prix Vente

0,5775

Volume échangé

55 915

0,5622 Fourchette du Jour 0,65989

0,2881 Plage de 52 semaines 1,344

Cap du marché

38,192M

Clôture Veille

0,6423

Ouverture

0,65989

Dernière Transaction

1600

0.5622

Dernière heure de transaction

18:26:00

Volume financier

US$ 34 702

VWAP

0,620621

Volume moyen (3 m)

US$ 0

Actions en circulation

67 933 289

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-21,86

Bénéfice par action (BPA)

-0,04

Chiffre d'affairess (LTM)

158,08k

Bénéfice net (LTM)

-2,78M

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experience... Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.archbiopartners.com

Siège social

Toronto, Canada

Fondé

ARch Biopartners Inc (QB) est coté dans le secteur Healthcare de la OTC Markets avec le ticker ACHFF. Le dernier cours de clôture d'ARch Biopartners (QB) était de US$0,64. Au cours de la dernière année, les actions de ARch Biopartners (QB) ont été négociées dans une fourchette de prix de US$ 0,2881 à US$ 1,344.

ARch Biopartners (QB) compte actuellement 67 933 289 actions en circulation. La capitalisation boursière d'ARch Biopartners (QB) est de US$38,19 million. ARch Biopartners (QB) a un ratio cours/bénéfice (ratio PE) de -21.86.

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

TORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF...

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.0787	16.2771458118	0.4835	0.79	0.4835	73414	0.65597966	CS
4	0.2372	72.9846153846	0.325	0.79	0.3033	40325	0.50476049	CS
12	0.1536	37.5917767988	0.4086	0.79	0.2881	30714	0.41472261	CS
26	-0.3313	-37.0789031897	0.8935	1.0165	0.2881	31321	0.54942981	CS
52	-0.7818	-58.1696428571	1.344	1.344	0.2881	32663	0.76481679	CS
156	-1.0278	-64.641509434	1.59	1.88	0.2881	19790	0.98520504	CS
260	-0.4847	-46.2985958544	1.0469	4.13	0.2881	17757	1.26704033	CS

ACHFF - Frequently Asked Questions (FAQ)

What is the current ARch Biopartners Inc (QB) share price?

The current share price of ARch Biopartners Inc (QB) is US$ 0,5622

How many ARch Biopartners Inc (QB) shares are in issue?

ARch Biopartners Inc (QB) has 67 933 289 shares in issue

What is the market cap of ARch Biopartners Inc (QB)?

The market capitalisation of ARch Biopartners Inc (QB) is USD 38,19M

What is the 1 year trading range for ARch Biopartners Inc (QB) share price?

ARch Biopartners Inc (QB) has traded in the range of US$ 0,2881 to US$ 1,344 during the past year

What is the PE ratio of ARch Biopartners Inc (QB)?

The price to earnings ratio of ARch Biopartners Inc (QB) is -21,86

What is the cash to sales ratio of ARch Biopartners Inc (QB)?

The cash to sales ratio of ARch Biopartners Inc (QB) is 391,63

What is the registered address of ARch Biopartners Inc (QB)?

The registered address for ARch Biopartners Inc (QB) is 545 King Street West, Toronto, Ontario, M5V 1M1

What is the ARch Biopartners Inc (QB) website address?

The website address for ARch Biopartners Inc (QB) is www.archbiopartners.com

Which industry sector does ARch Biopartners Inc (QB) operate in?

ARch Biopartners Inc (QB) operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ARch Biopartners Inc (QB) (ACHFF)

ARch Biopartners Inc (QB) (ACHFF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de ARch Biopartners Inc (QB)

ACHFF Dernières nouvelles

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

ACHFF - Frequently Asked Questions (FAQ)

ACHFF Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités